Nipah virus, a highly lethal pathogen with case fatality rates between 40% and 90%, poses a complex challenge during pregnancy due to its ability to cross the placental barrier in animal models.
While human vertical transmission remains unproven, physiological shifts in gestation may heighten maternal susceptibility to severe systemic infection.
A comprehensive review published in Frontiers in Public Health synthesizes current epidemiological data and experimental findings, highlighting that while the virus readily infects reproductive tissues in mammalian models, documented human cases during pregnancy remain exceptionally rare. This reveals a critical gap in our understanding of how this paramyxovirus—which relies on ephrin-B2 and ephrin-B3 cell receptors to trigger systemic vasculitis—interacts with the human maternal-fetal interface.
Clinical Insights for Patient Management
- No Confirmed Vertical Transmission: Despite evidence of the virus breaching the placenta in animal studies, no human case has yet confirmed the virus passing directly from mother to fetus.
- Heightened Vulnerability: The mid-gestational window may leave mothers more susceptible to the virus’s rapid, inflammatory progression.
- Diagnostic Nuance: Detecting the virus in neonates requires precise laboratory techniques—specifically PCR and serial antibody monitoring—to distinguish between passive maternal immunity and true congenital infection.
Physiological Vulnerability and Viral Pathogenesis
The Nipah virus genome, spanning 18.2 kilobases, encodes six structural proteins that facilitate its aggressive systemic tropism. Following mucosal exposure, the virus initiates replication in respiratory epithelial cells before disseminating into vascular endothelial cells. This process triggers syncytium formation—a fusion of cells that leads to severe inflammation and vasculitis—and allows the pathogen to circulate freely or bound to leukocytes, reaching the brain, lungs, and kidneys.
Pregnancy introduces unique immunological conditions that complicate this progression. The gestational cycle oscillates between pro-inflammatory and tolerogenic phases; the mid-gestational period, specifically, relies on regulatory T cells and M2 macrophages to sustain maternal-fetal symbiosis. This attenuation of cell-mediated defenses coincides with the period when Nipah virus establishes systemic viremia, potentially lowering the threshold for fulminant central nervous system pathology and acute respiratory distress syndrome.
Experimental Evidence of Placental Crossing
Research using pregnant animal models provides the most definitive look at the virus’s reproductive impact. In studies involving pregnant cats, investigators identified high concentrations of viral genomic material within placental structures, amniotic fluid, and fetal organs. These findings demonstrate that the virus is biologically capable of inducing degenerative placentitis and fetal pulmonary vasculitis.
Clinical data from human outbreaks, while limited, offers a different perspective. A case in Faridpur, Bangladesh, involved a woman who survived laboratory-confirmed acute Nipah encephalitis and later delivered a healthy infant. Neonatal testing revealed the absence of viral RNA but the presence of maternal IgG antibodies, confirming that the infant received passive humoral protection rather than an active congenital infection.
| Model/Case | Observation | Key Finding |
|---|---|---|
| Cat | Subcutaneous inoculation | Viral RNA in fetal brain/liver/lungs |
| Human (2020) | Post-recovery pregnancy | Passive IgG transfer, no active infection |
Risks and Precautions During Pregnancy
Clinical management of Nipah virus during pregnancy is restricted by a lack of approved antivirals and known teratogenic risks. Ribavirin is strictly contraindicated throughout gestation due to its potential to cause birth defects. Favipiravir has also exhibited teratogenic effects in preclinical models, rendering it unsuitable for pregnant patients.
Patients residing in or traveling to regions where Nipah virus is endemic—such as areas of Bangladesh and India—should strictly avoid consuming raw date palm sap or handling sick livestock.
Any individual presenting with high fever, headache, myalgia, or respiratory symptoms in these regions must seek immediate medical evaluation. Because symptoms often overlap with common obstetric complications, early disclosure of potential zoonotic exposure to healthcare providers is essential for rapid diagnostic testing and the initiation of supportive critical care.
Future Directions in Immunotherapy
Remdesivir, which demonstrated survival efficacy in non-human primate challenge models, remains a candidate for maternal salvage therapy due to safety data collected during its use for COVID-19 in pregnancy. The monoclonal antibody m102.4 is currently under investigation as a potential immunotherapeutic, though its large molecular structure limits its ability to cross the placenta in early pregnancy.
The fundamental question of whether the virus can induce subclinical vertical transmission in humans—or if maternal immune responses are sufficient to neutralize the pathogen before fetal exposure—remains unanswered. Addressing this requires the integration of pregnancy-specific pharmacokinetic and reproductive toxicology studies into the development of all future Nipah vaccines and monoclonal antibodies.
References
- Zhan, J., Deji, D., Zhong, C., & Qing, X. (2026). Nipah virus and pregnancy: a comprehensive review of risks, clinical management, and prevention. Frontiers in Public Health.
- World Health Organization (WHO). Nipah virus fact sheet.
- Centers for Disease Control and Prevention (CDC). Nipah virus (NiV) clinical overview.